<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Fagiani E</dc:creator>
  <dc:creator>Christofori G</dc:creator>
  <dc:date>2013</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Tie-1 and Tie-2 tyrosine kinase receptors are expressed specifically on vascular endothelial cells and on a certain subtype of macrophages implicated in angiogenesis, thus, they have been a major focus of angiogenesis research. Tie-1 and Tie-2 are essential for vascular maturation during developmental, physiological and pathological angiogenesis. Angiopoietin 1-4 (Ang-1-4) have been identified as bona fide ligands of the Tie-2 receptor, while Tie-1 remains an orphan receptor which is able to heterodimerize with Tie-2 and to modulate Tie-2 signal transduction. The most exhaustively studied angiopoietins are Ang-1 and Ang-2. Ang-1 is a critical player in vessel maturation and it mediates migration, adhesion and survival of endothelial cells. Ang-2 disrupts the connections between the endothelium and perivascular cells and promotes cell death and vascular regression. Yet, in conjunction with VEGF, Ang-2 promotes neo-vascularization. Hence, angiopoietins exert crucial roles in the angiogenic switch during tumor progression, and increased expression of Ang-2 relative to Ang-1 in tumors correlates with poor prognosis. Its central role in the regulation of physiological and pathological angiogenesis makes the angiopoietin/Tie signaling pathway a therapeutically attractive target for the treatment of vascular disease and cancer.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/53325</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.canlet.2012.08.018</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/22922303</dc:relation>
  <dc:source>Cancer letters. - 2013</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Angiopoietins</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Neoplasms</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Neovascularization, Pathologic</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Receptor, TIE-1</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Receptor, TIE-2</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Signal Transduction</dc:subject>
  <dc:title xmlns:ns8="xml" ns8:lang="en">Angiopoietins in angiogenesis.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
